Elironrasib

(Synonyms: RMC-6291)
3 Cited Publications
Customer Review

Based on 3 publication(s) in Google Scholar

Elironrasib is an orally active and covalent inhibitor of KRASG12C(ON). Elironrasib forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Thus, Elironrasib prevents KRASG12C(ON) from signaling via steric blockade of RAS effector binding. Elironrasib inhibits ERK signaling and induced apoptosis in KRASG12C-mutant H358 cells. Elironrasib also inhibits the proliferation of KRASG12C mutant cells with a median IC50 of 0.11 nM.

For research use only. We do not sell to patients.

  • Purity: 99.42%
  • CAS No.: 2641998-63-0
  • Formula: C55H78FN9O8
  • Molecular Weight:1012.26
  • Storage:
    Powder   -20°C, 3 years ; In solvent   -80°C, 6 months , -20°C, 1 month
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
Customer Validation & Images
WBCell Proliferation/Viability AssayFlow Cytometry
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • WB

All Ras Isoforms

More

All ERK Isoforms

More
100 mg

Get Quote In-stock

Please select quantity
Amount: USD 0.00